First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma

Multiple myeloma (MM) remains incurable despite the number of novel therapies that have become available in recent years. Occasionally, a patient with MM will develop an amyloid light-chain (AL) amyloidosis with organ dysfunction. Chimeric antigen receptor T-cell (CART) therapy has become a promisin...

Descripción completa

Detalles Bibliográficos
Autores principales: Oliver-Caldes, Aina, Jiménez, Raquel, Español-Rego, Marta, Cibeira, Maria Teresa, Ortiz-Maldonado, Valentín, Quintana, Luis F, Castillo, Paola, Guijarro, Francesca, Tovar, Natalia, Montoro, Mercedes, Benitez-Ribas, Daniel, Bataller, Alex, González-Navarro, E Azucena, Cid, Joan, Lozano, Miquel, Perez-Amill, Lorena, Martin-Antonio, Beatriz, Mena, Mari-Pau, Moreno, David F, Rodríguez-Lobato, Luis Gerardo, Campistol, Josep Maria, Calvo, Gonzalo, Bladé, Joan, Rosiñol, Laura, Juan, Manel, Pascal, Mariona, Urbano-Ispizua, Alvaro, Fernández de Larrea, Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655576/
https://www.ncbi.nlm.nih.gov/pubmed/34876408
http://dx.doi.org/10.1136/jitc-2021-003783

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8655576/
https://www.ncbi.nlm.nih.gov/pubmed/34876408
http://dx.doi.org/10.1136/jitc-2021-003783

Ejemplares similares